A European, Observational, Prospective Trial of Trabectedin Plus Pegylated Liposomal Doxorubicin in Patients with Platinum-Sensitive Ovarian Cancer.

Oncologist · 2021 · PMC8018301 · PMID 33289956

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Recent results of a large retrospective analysis of real‐life clinical data from 1,921 patients with ovarian cancer showed a trend for increased rates of germline or somatic BRCA testing, with 25% of patients tested in 2011 to 69% in 2018, largely because of the targeted treatment opportunities with PARP inhibitors [ 22 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.